Therapeutic efficacy assessed by FDG-PET/CT scans and serum CRP levels. Coronal and axial FDG-PET/CT images (A) before dabrafenib, (B) best response under dabrafenib, (C) recurrent disease under dabrafenib, and (D) under dual combined dabrafenib/trametinib treatment. Note the bone marrow response under dabrafenib with focal recurrence in the iliac bone (arrow). (E) Longitudinal CRP levels before and after initiation of dabrafenib/trametinib treatment. Prednisone therapy was initiated at 20 mg per day and rapidly tapered to a dose of 2.5 mg per day.